Señales en vivo de SRRA | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 dic 1970 @ 19:00):

Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs...

Stats
Volumen de hoy	0.00
Volumen promedio	651 457
Capitalización de mercado	0.00
EPS	$0 ( 2022-08-04 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-8.34
ATR14	$0.324 (0.59%)

Insider Trading

Date	Person	Action	Amount	type
2022-07-01	Vivo Opportunity, Llc	Sell	431 947	Common Stock
2022-07-01	Vivo Opportunity, Llc	Sell	75 749	Series A Warrants
2022-07-01	Orbimed Advisors Llc	Sell	226 704	Common Stock
2022-07-01	Orbimed Advisors Llc	Sell	170 437	Series A Warrants
2022-07-01	Ashiya Mona	Sell	226 704	Common Stock

INSIDER POWER
-97.17
Last 99 transactions
Buy: 4 604 902 \| Sell: 10 646 034

Volumen Correlación

Largo: 0.15 (neutral)

Corto: -0.71 (moderate negative)

Signal:(77.923) Neutral

Sierra Oncology Inc Correlación

10 Correlaciones Más Positivas
TA	0.981
IIN	0.98
ECHO	0.98
MLVF	0.979
SIOX	0.972
ATCX	0.971
KRTX	0.969
MOR	0.968
EXFO	0.965
CRTO	0.963

10 Correlaciones Más Negativas
BIOL	-0.972
MRBK	-0.971
WTER	-0.971
CYXT	-0.971
PIII	-0.966
UTME	-0.965
BCAB	-0.963
SMFL	-0.961
UTMD	-0.958
RVSB	-0.957

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Sierra Oncology Inc Correlación - Moneda/Commodity

0.48
( neutral )

0.75
( moderate )

-0.14
( neutral )

0.32
( neutral )

0.60
( weak )

-0.68
( moderate negative )

Sierra Oncology Inc Finanzas

Annual	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-7.14

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-7.14

FY	2020
Ingresos:	$300 000
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-7.70

FY	2019
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-30.30

Financial Reports:

No articles found.

Sierra Oncology Inc

Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California. As of July 1, 2022, Sierra Oncology, Inc. operates as a subsidiary of GSK plc.